{"id":"W2694871785","doi":"10.1200/jco.2017.35.15_suppl.5032","title":"Efficacy, safety, tolerability, and pharmacokinetics of EPI-506 (ralaniten acetate), a novel androgen receptor (AR) N-terminal domain (NTD) inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC) progressing after enzalutamide and/or abiraterone.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Tolerability; Enzalutamide; Pharmacokinetics; Prostate cancer; Adverse effect; Internal medicine; Abiraterone acetate; Gastroenterology; Nausea; Pharmacology; Dosing; Androgen receptor; Oncology; Urology; Cancer; Androgen deprivation therapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005120673,0.0004058586,0.0004632068,0.0001925456,0.0001236718,0.0002959659,0.0002624092,0.000371586,0.001316676],"category_scores_gemma":[0.0006652539,0.0002496854,0.0003910299,0.0002285651,0.0003497154,0.0004425145,0.0001186531,0.0008310031,0.0003073751],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003423643,"about_ca_system_score_gemma":0.0002760905,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007121775,"about_ca_topic_score_gemma":0.001328878,"domain_scores_codex":[0.999828,0.00007703997,0.00001256514,0.00002515191,0.000029211,0.00002810872],"domain_scores_gemma":[0.9996945,0.00007177395,0.0001019115,0.00002022243,0.0000178056,0.00009389198],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.4081772,0.03148916,0.05007456,0.0008654231,0.0007278525,0.0008400443,0.0007418246,0.006613003,0.2191062,0.0001820633,0.001796957,0.2793858],"study_design_scores_gemma":[0.03974161,0.7633355,0.1648381,0.00003712714,0.0005360683,0.001512648,0.0001446731,0.00308978,0.02366367,0.0001420351,0.002917476,0.00004128463],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9984946,0.0006535974,0.0001717806,0.00004094906,0.000005125743,0.00009682466,0.0001499004,0.0000223531,0.0003648092],"genre_scores_gemma":[0.9983985,0.0003491825,0.0002753741,0.00006101387,0.00001877653,0.00006465062,0.0002813646,0.000006044758,0.0005450475],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001316676,"threshold_uncertainty_score":0.004404664,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1093047001415817,"score_gpt":0.4681243312694845,"score_spread":0.3588196311279028,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}